Related Experiment Video
Updated: Jul 16, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Why should we still care about oncogenes?
Kathleen M Diehl1, Evan T Keller, Kathleen M Woods Ignatoski
1Department of Urology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0940, USA.
Abstract:
Although oncogenes and their transformation mechanisms have been known for 30 years, we are just now using our understanding of protein function to abrogate the activity of these genes to block cancer growth. The advent of specific small-molecule inhibitors has been a tremendous step in the fight against cancer and their main targets are the cellular counterparts of viral oncogenes. The best-known example of a molecular therapeutic is Gleevec (imatinib). In the early 1990s, IFN-alpha treatment produced a sustained cytologic response in approximately 33% of chronic myelogenous leukemia patients. Today, with Gleevec targeting the kinase activity of the proto-oncogene abl, the hematologic response rate in chronic myelogenous leukemia patients is 95% with 89% progression-free survival at 18 months. There are still drawbacks to the new therapies, such as drug resistance after a period of treatment, but the drawbacks are being studied experimentally. New drugs and combination therapies are being designed that will bypass the resistance mechanisms.
Insights
Targeting oncogenes with small-molecule inhibitors, like Gleevec for chronic myelogenous leukemia, has revolutionized cancer treatment. Ongoing research addresses challenges such as drug resistance to improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Oncogene mechanisms have been understood for decades, but targeting their protein function to inhibit cancer growth is a recent advancement.
- Small-molecule inhibitors represent a significant breakthrough in cancer therapy, primarily targeting cellular oncogene counterparts.
- Gleevec (imatinib) is a prime example of a molecular therapeutic agent.
Purpose of the Study:
- To highlight the impact of small-molecule inhibitors in cancer treatment.
- To compare the efficacy of traditional therapies with targeted molecular therapies.
- To discuss the challenges and future directions in oncogene-targeted cancer therapy.
Main Methods:
- Review of existing literature on oncogenes and small-molecule inhibitors.
- Comparison of treatment outcomes for chronic myelogenous leukemia (CML) using IFN-alpha versus Gleevec.
- Discussion of experimental studies addressing drug resistance mechanisms.
Main Results:
- Gleevec targets the kinase activity of the proto-oncogene abl, significantly improving CML treatment.
- Hematologic response rates in CML patients treated with Gleevec are 95%, with 89% progression-free survival at 18 months.
- While drug resistance is a challenge, new therapies and combination treatments are being developed.
Conclusions:
- Targeted molecular therapies, exemplified by Gleevec, have dramatically improved cancer treatment efficacy.
- Further research is essential to overcome drug resistance and enhance long-term patient survival.
- The development of novel drugs and combination strategies holds promise for future cancer therapy.
Related Concept Videos
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:18Cancer
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...